PMID- 25846583
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20220321
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 137
IP  - 8
DP  - 2015 Oct 15
TI  - Postmenopausal hormone therapy-also use of estradiol plus 
      levonorgestrel-intrauterine system is associated with an increased risk of 
      primary fallopian tube carcinoma.
PG  - 1947-52
LID - 10.1002/ijc.29549 [doi]
AB  - Data on the possible impact of postmenopausal hormone therapy (HT) on the 
      incidence of rare primary fallopian tube carcinoma (PFTC) are scarce. Therefore, 
      we conducted a nationwide case-control study analyzing the association between 
      the use of different HTs and PFTC. All women aged 50 years or older with an 
      incident PFTC (n = 360) during 1995-2007 were identified from the Finnish Cancer 
      Registry. For each case of PFTC, ten age- and place of residence-matched controls 
      were selected from the Finnish National Population Register, which also provided 
      information on parity. Data on HT purchases were received from the Prescription 
      Register, and data on hysterectomies and sterilizations from the National Care 
      Register. Controls with a salpingectomy before the PFTC diagnosis of the 
      respective case were excluded. The PFTC risk in relation to different HTs was 
      estimated with a conditional logistic regression model, adjusted for parity, age 
      at last delivery, hysterectomy and sterilization. The use for five years or more 
      of estradiol combined with levonorgestrel-releasing-intrauterine system (odds 
      ratio 2.84, 95% confidence interval 1.10-7.38) and sequential estradiol-progestin 
      therapy (EPT; 3.37; 2.23-5.08) were both linked with increases in the risk of 
      PFTC, while the risk with use of estradiol-only therapy or continuous EPT was not 
      statistically significantly increased. The OR for the use of tibolone for one 
      year or more was 1.56 (0.55-4.41). The use of HT is related to an increased risk 
      of PFTC, particularly when a progestin component is intrauterine or systemic 
      progestin is given in sequential manner.
CI  - (c) 2015 UICC.
FAU - Koskela-Niska, Virpi
AU  - Koskela-Niska V
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, FI-00029 
      HUS, Finland.
FAU - Pukkala, Eero
AU  - Pukkala E
AD  - Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer 
      Research, Unioninkatu 20, Helsinki, FI-00130, Finland.
AD  - School of Health Sciences, FI-33014 University of Tampere, Finland.
FAU - Lyytinen, Heli
AU  - Lyytinen H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, FI-00029 
      HUS, Finland.
FAU - Ylikorkala, Olavi
AU  - Ylikorkala O
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, FI-00029 
      HUS, Finland.
FAU - Dyba, Tadeusz
AU  - Dyba T
AD  - Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer 
      Research, Unioninkatu 20, Helsinki, FI-00130, Finland.
AD  - Public Health-Cancer Policy Support, European Commission DG Joint Research 
      Centre, Institute for Health and Consumer Protection, Ispra, I-21027, Italy.
LA  - eng
PT  - Journal Article
DEP - 20150421
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 4TI98Z838E (Estradiol)
RN  - 5W7SIA7YZW (Levonorgestrel)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Drug Therapy, Combination/adverse effects
MH  - Estradiol/administration & dosage/*adverse effects
MH  - Estrogen Replacement Therapy/*adverse effects
MH  - Fallopian Tube Neoplasms/*chemically induced/*epidemiology
MH  - Female
MH  - Finland/epidemiology
MH  - Humans
MH  - Levonorgestrel/administration & dosage/*adverse effects
MH  - Logistic Models
MH  - Middle Aged
MH  - Postmenopause
MH  - Risk Factors
OTO - NOTNLM
OT  - estrogen
OT  - hysterectomy
OT  - levonorgestrel intrauterine system
OT  - parity
OT  - progestin
OT  - sterilization
OT  - tibolone
EDAT- 2015/04/08 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/04/08 06:00
PHST- 2014/11/19 00:00 [received]
PHST- 2015/03/15 00:00 [revised]
PHST- 2015/03/23 00:00 [accepted]
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1002/ijc.29549 [doi]
PST - ppublish
SO  - Int J Cancer. 2015 Oct 15;137(8):1947-52. doi: 10.1002/ijc.29549. Epub 2015 Apr 
      21.